




Xlife sciences

where innovation leads to success



BUILDING THE BRIDGE FROM
RESEARCH AND DEVELOPMENT TO HEALTHCARE MARKETS

Mission Statement

Xlife Sciences is a publicly listed life sciences incubator and accelerator in Europe. With proven industry contacts and a clear focus on the successful proof of concept, we do not only deliver an exit but also keep our upside potential with milestones and royalties.


ACCESS TO A UNIQUE PORTFOLIO in a growth segment.

LIQUIDITY AND TRANSPARENCY as a publicly listed company.

RISK REDUCTION by clear focus on proof of concept and timely exits.

LEAN AND COST-EFFECTIVE STRUCTURE DNA in all projects.

WHERE WE ADD VALUE TO OUR PORTFOLIO PROJECTS



Xlife Sciences is a Swiss company with focus on the performance and growth of promising technologies in the life sciences industry.

>5M

SHARES

The company has a share capital of CHF 5,265,723, which is divided into 5,265,723 shares with a nominal value of CHF 1.00 each.

+/- 230M

MARKET CAPITALIZATION¹

The share has been tradable on the SIX Swiss Exchange in the "Sparks" segment since February 11, 2022.

46.4%

FREE FLOAT²

46,6% held by Founders, 7.0% held by Management & Board of Directors.

>10

INNOVATION PARTNERS

We collaborate with 15 prominent University Partners and Research Institutes, as well as with over 100,000 scientists.

>20

PROJECTS COMPANIES

An optimal risk diversification with 23 project companies based on our investment themes (Technology Platforms, Biotech & Therapies, Medical Technology, Artificial Intelligence).

>10

EMPLOYEES

On 31 December 2020, we had 9 full time employees, which grew to 11 employees and 8 consultants as of 31 December 2021.

(1) in CHF / 08.03.2022

(2) rounded values



Oliver R. Baumann
Chief Executive Officer
Member of the Board of Directors



Carl von Halem
Chief Financial Officer



Dr. Frank Plöger
Chief Scientific Officer



Beat Kläui
Head of Accounting
and Taxes

MANAGEMENT



Dr. Bernhard Scholz
President of the Board
of Directors



Christian Faber
Member of the Board
of Directors



Mark S. Müller
Member of the Board
of Directors



Simon Schöni
Member of the Board
of Directors

BOARD OF DIRECTORS



**Prof. Dr. habil.
Michael B. Klein**
Member of the Board
of Directors and Head
of the Scientific Board
of Experts



Prof. Dr. Ernst Rietschel
Immunology Expert



**Prof. Dr. Hans-Georg
Rammensee**
Immunology Expert



**Prof. Dr. Johannes
Schumacher**
Human Genetics Expert



**Dr. med. Ralf
Oettmeier**
Head Physician at
Alpstein Clinic



**Dr. med. Uwe Rudolf
Max Reuter, DM**
Head Physician at
Klinik Im Leben



**Dr. rer. nat. Ludger
Grosse Hovest**
Expert in Immunology
and Antibodies




**Dr. Christoph
Brücher**
Industry Expert


SCIENTIFIC BOARD OF EXPERTS

Xlife Sciences addresses global disease burden with modern biotech approaches.


ADDRESSING GLOBAL DISEASE BURDEN...



TO ENTER THE LARGEST MARKETS.



BY USING MODERN TECHNOLOGIES...



TECHNOLOGY PLATFORMS	BIOTECH & THERAPIES	MEDICAL TECHNOLOGY	ARTIFICIAL INTELLIGENCE
<ul style="list-style-type: none"> Functional antibody screening Personalized medicine 	<ul style="list-style-type: none"> New modalities Reducing animal testing Cancer and CVD therapies 	<ul style="list-style-type: none"> 3D printing Neuroscanning Biomarker discovery Contactless monitoring 	<ul style="list-style-type: none"> Improving diagnostic Accelerated target identification

(1) Source: <https://ourworldindata.org/burden-of-disease>


(2) Source: <https://bit.ly/3sYYhA8>; <https://bit.ly/3mVwKfi>; <https://bit.ly/31s5qO2>; <https://bit.ly/3tfCpkn>; <https://bit.ly/3G0fbJj>; <https://bit.ly/3G00bqO>

Project Companies

Our investors benefit from an unique portfolio approach. Moreover, our portfolio of projects provides a strong risk diversification for investors.



QUADIRABIOSCIENCES




FUSE-AI

Note: Following companies are not shown: novaxomx GmbH, xprot GmbH, Novum Technologie GmbH (main project has not yet startet)

(1) No equity stake

Project Portfolio

The portfolio consists of market-to-market, equity and fully consolidated companies or in one case a license participation. Some companies are particularly highlighted ★ by Xlife management on the basis of internal evaluations.






STRONG FOCUS ON DACH REGION

- Xlife Sciences is headquartered in Zurich, Switzerland
- The majority (95%) of the projects are based in the DACH region



NETWORK

- International network in the pharmaceutical and biotechnology industry in Europe and also the US & Asia
- Xlife Sciences is a reliable partner for well-known universities and research institutes



INTERNATIONAL LICENSE AGREEMENTS

- Xlife Sciences has established a network and relationships with international firms primarily in Europe, but also in the US, Middle East and Asia
- Relationships with these companies offer significant potential for exits


Project companies

Innovation partner

Funding partner

Headquarter

Xlife Sciences synergies are a key driver of success. In the Xlife family we live synergies. Many use cases and agreements have grown genuinely between our partners.





Inventum Genetics GmbH is a Mainz based company, which is dedicated to identify new therapeutic approaches and biomarkers for common diseases based on mechanism driven human genetic data.

PROJECT OVERVIEW

Common diseases are caused by a combination of environmental factors and genetic risk factors. Inventum genetics analyses the genetic contribution to the cellular answer during externally caused pathomechanisms.

STATUS

The first project focuses on DNA-damage response, a well known mechanism, playing a role in cancers, neurodegenerative and age associated diseases. Different types of DNA damages have been set in immune cells.

NEXT STEPS

- Whole Genome Genotyping of 450 individuals
- RNA Sequencing of basis conditions and cells after stimuli
- Bioinformatic analysis of data
- Identification of targets

MARKET

The global market for DNA damage response drugs is predicted to grow at a CAGR of 21.33% over the forecast period of 2020-2030 and to reach USD 25 billion by 2030.

Source:

<https://www.businesswire.com/news/home/20200909005492/en/Global-DNA-Damage-Response-Drugs-Market-to-Reach-24848.8-Million-by-2030---ResearchAndMarkets.com>

INDICATION

- Diseases in which DNA damage response plays crucial role (cancer, neurodegenerative diseases, age associated diseases)

BUSINESS MODEL

- Outlicensing of targets
- Trade sale database

Incorporation

2020

Location

Mainz, Germany

Website

www.inventumgenetics.com

Stake Xlife

100%



palleos healthcare GmbH is a full service clinical research organisation (CRO) based in Wiesbaden, Germany.

PROJECT OVERVIEW

palleos healthcare aims to build a regulatory and operational bridge between preclinical and clinical development to implement innovative concepts for its customers. As a full service CRO, the company provides a wide range of services, ranging from clinical development to trial closure.

STATUS

In contrast to other Portfolio companies, palleos healthcare is an already established service provider and supports other portfolio companies.

INTERNATIONAL NETWORK

By using CRO-Alliance ONE, a platform under which palleos healthcare GmbH offers the execution of clinical trials beyond the German market by partnering with third party CROs in the EU and North America, palleos healthcare extends its services to Europe and the United States. The strategic alliance with Phaon scientific GmbH, a scientific study development group that offers a platform for professionals to discuss, promote, and perform research in the field of oncology based in Wiesbaden, Germany, enables the implementation of academic concepts.

Incorporation
2013

Location
Wiesbaden, Germany

Website
www.palleos.com

Stake Xlife
50%



Veraxa Biotech AG is a Swiss company founded in 2020, based in Zurich. The company focuses on microfluidic screening and development of antibody drug conjugates (ADCs) by an innovative click chemistry approach.

PROJECT OVERVIEW

The microfluidic high content screening approach enables Veraxa to screen millions of antibodies regarding their functionality and by that shorten the subsequent development time by two years. The click chemistry approach allows the combination of cytotoxic drugs with antibodies.

STATUS & NEXT STEPS

Screening and modulation of antibodies for external partners is ongoing.

MARKET

The current projects of Veraxa focuses on the development of antibodies for oncology. The global oncology drugs market size was valued at USD 141.33 billion in 2019 and is projected to reach USD 394.24 billion by 2027, at a CAGR of 11.6% during forecast period. The global obesity treatment market was valued at USD 8.39 billion in 2020 and is expected to reach USD 27.08 billion by year 2028, at a CAGR of 15.7%.

Source:

www.fortunebusinessinsights.com/oncology-drugs-market-103431
www.reportsanddata.com/report-detail/obesity-treatment-market

INDICATION

- Oncology

BUSINESS MODEL

The platform technology enables Veraxa to screen and modulate antibodies for external projects and to earn license fees for the antibodies.

Incorporation

2019

Location

Zurich, Switzerland

Website

www.veraxa.com

Stake Xlife

19,26%



alytas therapeutics

alytas therapeutic GmbH is a spin-off of the university of Jena (Germany) and is dedicated to develop novel therapeutic targets to treat adiposity.

PROJECT OVERVIEW

alytas therapeutics GmbH's project is a novel treatment form of obesity that makes use of anti-adipocyte antibodies and their immune mediated reduction of fat cells. This project is managed by Alytas Therapeutics GmbH in close cooperation with the University Hospital (Universitätsklinikum) Jena. The current treatment hypothesis of Alytas is based on in-vitro and in-vivo data from humans and animals.

STATUS & NEXT STEPS

Autoantibodies from a patient presenting with increased adipocyte degradation have been analyzed to identify the relevant epitope and to set up the screening assay. Immunization of mice has been initiated and as a next step the screening of functional antibodies will be performed.

MARKET

Given the current epidemic growth of obesity worldwide and its devastating associated co-morbidities, there is high demand for innovative, sustainable, and non-surgical forms of therapy for obesity with an acceptable side-effect profile and improved efficacy. The global antiobesity market is expected to grow from USD 1.46 billion in 2020 to USD 2.4 billion in 2021 at a compound annual growth rate (CAGR) of 64.4%. The market is expected to reach USD 5.42 billion in 2025 at a CAGR of 22.6%.

Source:

<https://www.businesswire.com/news/home/20210830005368/en/Anti-Obesity-Drugs-Global-Market-Report-2021---ResearchAndMarkets.com>

BUSINESS MODEL

- Development and outlicensing of prototype

Incorporation

2020

Location

Jena, Germany

Website

www.alytastherapeutics.com

Stake Xlife

51,04%

Improvement and GMP-manufacturing of small molecules



Inflamed pharma GmbH focused on the GMP-compliant development of active small molecules that have a special application or unfavourable properties for the formulation of medicinal products, such as poor water solubility or membrane compatibility.

PROJECT OVERVIEW

The most advanced project is ProcCluster®, which is based on procain, a commonly used local anesthesia. The formulation of ProcCluster allows a systemic administration of the compound. Besides the pain relief, it was shown to have anti-inflammatory as well as anti-viral effects.

STATUS

ProcCluster is currently used in individual healing trials for the treatment of inflammatory induced pain conditions like post-covid syndrome and rheumatic diseases without any obvious side effects.

NEXT STEPS

- ProcCluster: Set up of pre-clinical development for 2 indications
- Advance additional pipeline projects : DAZA-Tracer; (XYZ)

MARKET

Inflamed pharma aims to enter the market for inflammatory pain conditions. The global non-steroidal anti-inflammatory drugs (NSAIDs) market size is expected to reach USD 24.35 billion by 2027, exhibiting a CAGR of 5.8%.

Source:

www.fortunebusinessinsights.com

INDICATION

- Inflammatory pain conditions

BUSINESS MODEL

- Licences deal for ProcCluster
- Increasing the use of ProcCluster within the scope of license-free own production according to §13 2b AMG
- GMP compliant development and improvement of compounds for external partners

Incorporation

2019

Location

Jena, Germany

Website

www.inflamedpharma.com

Stake Xlife

75%



Ix therapeutics is dedicated to identify individualized therapeutic antibodies for oncology indications based on multi-omics patient data.

PROJECT OVERVIEW

Ix Therapeutics GmbH, a joint venture between Xlife and Individumed, is intended to use Individumed's AI-based platform nRavel®, which, together with Individumed's IndivuType multi-omics database, is intended to deliver more precise insights into and much better predictors for certain pathologies and diseases with high medical needs. The IndivuType database is a combined collection of high-quality multi-omics and accompanying clinical data from thousands of cancer patients combined with whole genome sequencing, transcriptomics, proteomics, and phosphoproteomics data. Ix Therapeutics GmbH uses the technology platform of Veraxa Biotech AG for the development of antibodies with the aim to discover modulatory and functional antibodies against several targets relevant for colorectal cancer that have been identified by Individumed's nRavel® platform.

STATUS

The joint venture is currently running Veraxas screening system to identify therapeutic antibodies for three different targets

MARKET

Based on a report published by Market Data Forecast, the global colorectal cancer market size was worth USD 15.7 billion in 2021. This value is forecasted to be growing at a CAGR of 2.63% to reach USD 17.88 billion by 2026.

INDICATION

- Colorectal cancer

BUSINESS MODEL

- The company aims to outlicense the identified antibodies

Incorporation

2021

Location

Hamburg, Germany

Website

www.ix-therapeutics.com

Stake Xlife

50%

Extracellular vesicles for inflammatory diseases

Lysatpharma.

Lysatpharma GmbH is german biotechnology company which focuses on regenerative medicine and new biomedical immunotherapies based on extracellular vesicles.

PROJECT OVERVIEW

Lysatpharma GmbH is developing novel immunotherapies for acute as well as chronic, systemic inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis or certain forms of diabetes. The patented approach of Lysatpharma GmbH is based on the use of extracellular vesicles, which are extracted from surplus production of high-quality tested blood products. These conserves are provided continuously by blood banks for clinical primary care. By repurposing unused and otherwise discarded blood products, Lysatpharma GmbH processes the precious material.

STATUS / NEXT STEPS

Currently, the company's R&D programme consists of four projects: (i) a new immunotherapy for rheumatoid arthritis, (ii) the treatment of multiple sclerosis, (iii) a treatment against the severe graft-versus-host disease ("GvHD") that is a major complication after allogeneic stem-cell transplantation in cancer patients, and (iv) a novel treatment option in the field of amyotrophic lateral sclerosis ("ALS"), a motor neurone disease causing the progressive loss of motor neurons.

MARKET

The market for extracellular vesicle is projected to have an exponential growth in the upcoming years. BCC research expects a CAGR of ca. 50% in the years between 2018 and 2023 from USD 25 million to USD 180 million. Current prognosis for the market of regenerative medicine is a growth from EUR 26 billion to EUR 130 billion between 2019 and 2025.

BUSINESS MODEL

The company aims to outline treatment approaches and to broaden the indication space.

Incorporation

2018

Location

Jena, Germany

Website

www.lysatpharma.com

Stake Xlife

25.2%

Antibody drug conjugates (ADCs) against cancer

QUADIRABIOSCIENCES

Quadira Biosciences AG was founded in 2021 and is dedicated to improve Antibody Drug Conjugates (ADCs) for the treatment of oncological indications.

PROJECT OVERVIEW

The company will use the technology platform of Veraxa Biotech AG for the development of novel Antibody Drug Conjugates (ADC) for the treatment of diverse oncological conditions with blockbuster potential. Moreover, QUADIRA BIOSCIENCES AG has access to the 3D CoSeedis™ technology platform of abc biopply AG. This 3D cell technology enables the replication of human tissue for reliable testing and characterization of antibodies without animal testing.

STATUS & NEXT STEPS

In a first screening round, it has identified 30 promising compounds. QUADIRA BIOSCIENCES AG modifies these antibodies with high accuracy and increase the quality of their active ingredient. The expected result are advanced, highly potent antibodies with higher cytotoxic activity and improved side effect profile for cancer therapy. The collaboration is intended to leverage both the advantages of Veraxa Biotech AG's advanced and proprietary position-true click-chemistry-based drug conjugation technology in combination with QUADIRA Biosciences AG's superior 3D cellular assay and assessment systems.

MARKET

The global solid tumor cancer treatment market was valued at USD 121.3 billion in 2018 and is expected to reach USD 424.6 billion by 2027, expanding at a CAGR of 15.0% from 2019 to 2027.

BUSINESS MODEL

- The company intends to outlicense the identified antibodies.

Incorporation

2021

Location

Solothurn, Switzerland

Website

www.quadirabiosciences.com

Stake Xlife

50%



Synimmune GmbH is a biotechnology company dedicated to the development of innovative and effective mono- and bispecific anti-tumour antibodies for the treatment of patients suffering from life-threatening diseases.

PROJECT OVERVIEW

Synimmune GmbH is currently focusing on two projects. One of the projects uses the monospecific antibody FLYSYN for the treatment of acute myeloid leukaemia ("AML") on patients at a stage of minimum residual disease ("MRD"). The effectiveness and compatibility of the antibody has already been proven in first treatment attempts. The company is currently preparing for a Phase II clinical study to further demonstrate efficacy of the antibody. The company initially tried to combine Phase I with Phase IIa, which led to mixed results not ready for use. As a result, the company decided to carry out a Phase II study, which is currently ongoing.

The other project is a FLT3xCD3 bispecific antibody ("TACSYN") for the therapy of AML and acute lymphoblastic leukaemia ("ALL") in patients whose disease is characterised by a relatively high and growing number of tumour cells. The project is based on bispecific antibodies for the therapy of antitumor immunology. Synimmune GmbH has completed the preclinical characterisation of TACSYN with high target specificity. In addition, Synimmune has developed a GMP (Good Manufacturing Practice) manufacturing process for TACSYN.

MARKET

Amid the COVID-19 crisis, the global market for Acute Myeloid Leukemia (AML) Therapeutics estimated at USD 476.9 Million in the year 2020, is projected to reach a revised size of USD 976.2 Billion by 2026, growing at a CAGR of 12.6% over the analysis period.

INDICATION

- Acute Myeloid Leukemia

BUSINESS MODEL

- Synimmune GmbH aims to outlicense the developed antibody
- Further identification of new antibodies with the bispecific antibody platform

*Stake Xlife: 37,36% via Synimmune Equity AG, Liechtenstein

Incorporation

2010

Location

Tübingen, Germany

Website

www.synimmune.de

Stake Xlife*

37.36%

Xprot GmbH is dedicated to develop new therapeutic approaches for lung cancer.

PROJECT OVERVIEW

The American Cancer Society estimates for lung cancer in 2022 about 236,740 new cases and about 130,180

deaths, only in the U.S. The company has identified a gene which is downregulated in tumor samples of patients.

The downregulation of the gene leads to uncontrolled cell cycle progression and immune evasion of the tumor. It was shown that restoration of the gene in vitro leads to a reduction of tumor cells. The company's research activities are focused on strategies to develop a gene therapy with the aim to restore expression of the gene in tumor tissue to stop uncontrolled tumor growth and stimulate the immune response. Besides the therapeutic use of the gene, the company is also evaluating the gene as a diagnostic biomarker. The combination of biomarker and therapeutic target is a very attractive combination for a future personalised medicine approach.

NEXT STEPS

After the validation of the approach in lung cancer, the company aims to broaden the indication space towards additional cancer indications.

MARKET

The global market for lung cancer therapeutics should grow from USD 17.9 billion in 2018 to USD 26.3 billion by 2023, increasing at a compound annual growth rate (CAGR) of 8.0% from 2018 to 2023.

INDICATION

Lung Cancer

BUSINESS MODEL

Tradesale or Outlicensing

Incorporation

2022

Location

Mainz, Germany


Website

in creation

Stake Xlife

100%

3D Printing of biomaterials



Axenoll Life Sciences AG is a swiss medical technology company which is focused on the 3D printing of biomaterials for applications in the medical and biotechnology sector.

PROJECT OVERVIEW

The 3D printing technology of the company is based on a screen printing technology. It allows the gently printing of a broad range of materials and of fine structures like channels (>50µm). The modular construction of the printers enables the company to easily upscale the printing without losing the precision. The screen printing technology can be used for a broad range of applications like wound healing and small implants.

STATUS & NEXT STEPS

The portfolio includes a wide range of 3D products such as wound meshes, micro scalpels, screening chips or human micro tissue. The focus is mainly on diagnostics, but also on medical applications. Microarrays, printed membranes, bone implants, medical sensors or organoids can be produced in high volumes and identical units as well as in variable form and permeability. The Axenoll products are in the preclinical development stage. However, there are already customer requests from the industry to replace existing costly manufacturing processes for marketed products by the more efficient Axenoll's 3D screen printing production process.

MARKET

The current projects are focused on the regeneration of bones and burn care. The market size for the orthopedic implants market was valued at USD 45,901 million in 2017, and is projected to reach \$66,636 million by 2025, growing at a CAGR of 4.7% from 2018 to 2025. The market size for burn care was valued at USD 2.1 billion in 2020 and is projected to reach USD 3.7 billion in 2028 growing at a CAGR of 6.9% in the research period.

BUSINESS MODEL

The company will further industrialize the projects, ranging from development task to industrial production on a large scale. Its customers will be pharmaceutical, medical and biotech companies. After customer-specific product development, Axenoll 3D Printing GmbH will take over series production or grant sublicences to customers, who can then manufacture their product themselves.

Incorporation

2014

Location

Zurich, Switzerland

Website

www.axenoll.com

Stake Xlife

13,97%



clyxop medical devices GmbH is German biotechnology company focused on the development of biocellulose based tubes to replace hollow structures in damaged organs.

PROJECT OVERVIEW

Based on biocellulose, clyxop devices GmbH is developing tubes that can be used to bridge damage to hollow organs and stimulate tissue regeneration and forming. Cellulose production by Acetobacter was first described in 1886, but has only found its way into the scientific world since the 1980s. In this way, bacteria are bred in a 14- day-process in the laboratory. A decisive advantage over typically small, synthetic active ingredients is the high biological specificity of the tubes, whereas a surgical therapy of hollow organs of the abdomen is a challenge and often leads to subsequent complications.

STATUS & NEXT STEPS

First in vivo trials in pig for bile duct replacement have been conducted successfully. The company is now looking for methods to improve the time of the production.

MARKET

Based on literature data it is estimated that bile duct replacement is necessary in around 100.000 patients world wide per year. Based in the flexibility of the product the tubes can be used for the replacement of additional hallow structures in the body.

BUSINESS MODEL

The company aims to outlicense or co-develop the product.

Incorporation

2019

Location

Erfurt, Germany

Website

www.clyxopdevices.com

Stake Xlife

70%

3D Printing of drug delivery systems



Laxxon Medical Corp. Is focused on the development, production and commercialiation of an innovative drug delivery system for the controlled release of pharmaceutical actives.

PROJECT OVERVIEW

An additive manufacturing process enables the production of multi-layered pharmaceutical application forms such as tablets. With this technology, tablets can be provided with geometric structures that enable the distribution of one or more active pharmaceutical ingredients. This structure allows a delayed and, as a result, consistent release of the active ingredients in the body over a longer period of time, improving their effectiveness for the benefit of patients. The 3D screen printing process enables both the production of very small quantities (as required, for example, in clinical research) and the mass production of medicines necessary for the pharmaceutical industry. In addition, this special process makes it possible to create a counterfeit-proof "watermark" inside the tablet to protect it against counterfeit medicines, which is not possible with conventional manufacturing processes.

MARKET

Global controlled release drug delivery market size was valued at USD 32.8 billion in 2019 and is anticipated to expand at a CAGR of 7.5% during 2020-2026. Rapidly increasing geriatric and pediatric population is fueling the demand for the market, due to high cases prescription non-adherence in this age-group.

BUSINESS MODEL

- The aim of Laxxon Medical AG is to grant sub-licenses of this new technology to selected companies in the pharmaceutical industry.

Incorporation

2017

Location

Nevada, USA

Website

www.laxxonmedical.com

Stake Xlife

4.7%

Early detection of neurodegenerative diseases



Saniva diagnostics GmbH, a spin-off of the University Hospital Jena, is a German medical technology company based in Erfurt. It specialized on the development of a screening instrument for the early detection of neurodegenerative diseases.

PROJECT OVERVIEW

Saniva diagnostics develops Neuromex, a costeffective easy to use screening device for the detection of Parkinsons disease (PD) before the clinical manifestation. It is based on the Falling-Stick test and can be used in GP practice. The device combines the hardware and the AI based analysis software.

STATUS

Two clinical trials will be conducted in 2022 to achive the Proof of concept for PD. The possibility to detect patients with prodromal Alzheimer`s disease with the Neuromex will be evaluated in clinical trial.

NEXT STEPS

- Generation of Norm-data in healthy individuals
- Clinical trial in patients with prodromal PD and prodromal Alzheimer`s disease
- CE certification and FDA approval

MARKET

The Neurological Biomarkers Market for Alzheimer's and Parkinson's disease was valued at USD 3,958.5 million in 2017, and is expected to reach USD 8,579.9 million by 2025, registering a CAGR of 10.1% from 2018-2025.

Source: www.alliedmarketresearch.com

INDICATION

- Parkinson Disease
- Alzheimer`s Disease

BUSINESS MODEL

- Distrubution of Neuromex to GE practice.
- Cloud solution for results enables distrubutor to improve granularity of results.
- The company is currently looking for partners to upscale Neuromex production
- Licensing discussions have been initiated.

Incorporation

2019

Location

Erfurt, Germany

Website

www.sanivadiagnostics.com

Stake Xlife

19%



VITRUVIA MEDICAL AG reprocesses clinical robotic instruments and single-use devices by providing a so-called "circular system" for surgical instruments and other clinical instruments.

PROJECT OVERVIEW

Under the label Project VITU-2019, VITRUVIA MEDICAL AG focuses on the hygienic and economical reprocessing of complex surgical instruments like the da Vinci system, the variety of their applications, construction and materials. The objective of VITU-2019 is to make available hygienically tested and economically reprocessed medical devices. The circular systems aims to save costs for hospital in a sustainable way.

Using a laser-based individual identification system, the company is able to track every device and ensure that every device is returned to the hospital from which it came. Further, the company develops applications based on machine learning algorithms and strategies using self-learning methods of artificial intelligence.

STATUS & NEXT STEPS

VITRUVIA MEDICAL AG has purchased and renovated a supply center in Schönebeck (Germany) and has further locations in Anglikon (Switzerland) and Berlin.

MARKET

The global market for robotic surgery systems is expected to see double-digit, year-on-year growth, reaching more than USD 9.7 billion by 2023. Pioneering robotics surgery firm Intuitive Surgical Inc. continues to dominate the overall robotics surgery market, accounting for more than USD 3.7 billion in sales of its da Vinci systems, instruments and accessories.

BUSINESS MODEL

- VITRUVIA Medical AG partners with hospitals to reprocess their clinical instruments
- On 11 May 2021, the shares of VITRUVIA MEDICAL AG were admitted to trading on the Munich Stock Exchange on the general open market segment.

Incorporation

2017

Location

Anglikon, Switzerland

Website

www.vitruvia-med.com

Stake Xlife

5.47%



x-kidney diagnostics GmbH focuses on the identification of innovative biomarkers in the area of kidney disease.

PROJECT OVERVIEW

The early diagnosis of kidney diseases is essential for their successful treatment and management. However, the early diagnosis is hampered by the lack of biomarkers for early stages. Currently, clinically validated biomarkers are recognized when the kidney is already damaged by 50%. Diabetic nephropathy is the most common cause of dialysis in Europe and the United States. x-kidney diagnostics GmbH focuses on the identification of novel biomarkers by a proteomic based research approach in the Alport syndrome, a glomerulonephropathy with well defined animal models. Based on the comparable histopathogenesis of different glomerulonephropathies, Alport syndrome was used as surrogate model. In animals (mice and dogs) with Alport syndrome over 100 differentially expressed proteins could be identified before the onset of the disease.

STATUS & NEXT STEPS

The most promising biomarker will be validated in a dataset of approximately 200 clinically well described Alport syndrome patients with serum, plasma and urine samples. After the successful validation of the biomarkers in humans, the next step is the development of diagnostic test for the early detection of kidney disease.

MARKET

The Kidney Function Tests Market is expected to register a CAGR of 5.62% during the forecast period, with a revenue of approximately USD 950 million in 2020, and it is expected to reach USD 1,267 million by 2026.

BUSINESS MODEL

The company is looking for partners to outlicense the identified biomarker.

Incorporation
2019

Location
Erfurt, Germany

Website
in creation

Stake Xlife
100%



X-nuclear diagnostics GmbH researches on technologies in the field of diagnostic for application in nuclear medicine.

PROJECT OVERVIEW

In nuclear medical diagnostics, patients are administered radioactive drugs which accumulate in various concentrations in human organs or tissues (depending on their pharmacological properties). Due to their radioactivity, their temporal and spatial distribution in the body can be detected externally and made visible through suitable measuring instruments. The company's liver-specific radiotracer for PET diagnostics is in an early stage of development; its effectiveness has been demonstrated in animals (in ovo). The PET tracer has high potential for clinical application because it is less toxic than other radiodiagnostics and can also be used for metal-heavy implants .

STATUS & NEXT STEPS

- Finalization of Tox-study
- Start of Clinical Development

MARKET

In the DACH region alone there are over 300 nuclear medicine specialists who could also use the PET tracer. If the centers in the US and Asia are included, sales potential is expected to exceed EUR 1 billion per year.

INDICATION

- Liver diseases

BUSINESS MODEL

- x-nuclear aims to outlicense the PET-tracer

Incorporation
2019

Location
Erfurt

Website
in creation

Stake Xlife
100%



Xsight Optics GmbH is a Jena based company, which is developing devices for contactless monitoring of health parameters as well as innovative solutions for the medical sector.

PROJECT OVERVIEW

«Vitus» is a mobile handheld optical sensor which allows simultaneously and contactless measurement of health parameters like heartrate, oxygen saturation, body temperature and resperytory rate. The parameters are measured via an integrated optical sensor and analyzed via AI based algorithms.

STATUS

The prototype will be developed for clinical applications like new born monitoring, but because of ist versatility also serve as seed for other markets like mobile stations in pharmacies or security applications in crowded places.

NEXT STEPS

- Development of prototype incl. clinical phase and certification
- Development of algorithms for additional areas:
 - Security application for stadiums
 - Recognition of stress situations

MARKET

The global market for fetal and neonatal monitors should grow from USD 4.8 billion in 2020 to USD 6.4 billion by 2025, at a compound annual growth rate (CAGR) of 6.1% for the period of 2020-2025. The fastest growing makret is the Asia Pacific market and the largest market is North America.

Source:

<https://www.mordorintelligence.com/industry-reports/global-fetal-and-neonatal-monitoring-market-industry>

INDICATION

- Fetal and neonatal monitoring
- Hospitals
- GP practice; pharmacies
- Security
- Stress monitoring

BUSINESS MODEL

- Development and outlicensing of prototype

Incorporation

2021

Location

Erfurt, Germany

Website

www.xsightoptics.com

Stake Xlife

80%



FUSE-AI

FUSE-AI is a Hamburg based e-health company with the aim to provide better medical care with intelligent software solutions. This overview focuses on the AI-supported software for radiology.

PROJECT OVERVIEW

The AI-supported software for radiology reduces the misdiagnoses of carcinomas and increases the findings per day by Radiologists. This increases reimbursement by insurance companies.

STATUS

Proof of concept is achieved for prostate carcinoma. The software was introduced at the Radiological Society of North America meeting in 2021. FUSE-AI is nominated for the Deutscher Zukunftspreis 2022.

NEXT STEPS

- Multicentric clinical study in three Swiss hospitals (Kantonsspital Aarau; Ospedale Regionale di Bellinzona e Valli; Universitätsspital Zürich)
- Expand software to additional carcinoma indications

MARKET

The global prostate cancer diagnostics market size was valued at USD 3.32 billion in 2020, and is expected to reach USD 7.65 billion by 2027, registering a CAGR of 13.2% from 2020-2022.

Source:

www.grandviewresearch.com/industry-analysis/prostate-cancer-diagnostics-market

INDICATION

- Prostate carcinoma
- Breast, Lung carcinoma

BUSINESS MODEL

- R&D of innovative AI dependend radiology solutions
- Partner for research projects
- Listed as an official Software as a Medical Device (SaaMD) developer and distributor in Europe by the Federal Institute for Drugs and Medical Devices (BfArM)

Incorporation

2016

Location

Hamburg, Germany

Website

www.fuse-ai.de

Stake Xlife

35%



> **Oliver R. Baumann**

CEO

oliver.baumann@xlifesciences.ch

+41 44 385 84 60



> **Carl v. Halem**

CFO

carl.halem@xlifesciences.ch

+41 44 385 84 60



> **Dr. Frank Plöger**

CSO


Frank.plöger@xlifesciences.ch

+41 44 385 84 60



Xlife sciences

where innovation leads to success



Xlife Sciences AG | Talacker 35 | CH-8001 Zurich | Switzerland | +41 (0) 44 385 84 60 | www.xlifesciences.ch